MedTrace Logo

Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)

NCT02728778 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2020-05-29

No results posted yet for this study

Summary

The main objective of the trial is to test whether a single application of botulinum toxin A into the glabellar region will lead to emotional stabilization in borderline personality disorder through paralysis of facial muscles/attenuation of negative emotions.

Conditions

  • Borderline Personality Disorder

Interventions

DRUG

incobotulinumtoxin A

Application of botulinum toxin A into the forehead

PROCEDURE

Acupuncture

Application of acupuncture into the forehead

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • HCTC · Hannover Clinical Trial Center HCTC GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-01
Primary Completion
2019-04-30
Completion
2019-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02728778 on ClinicalTrials.gov